Search

Your search keyword '"Forconi, Francesco"' showing total 15 results
Start Over Author "Forconi, Francesco" Journal leukemia & lymphoma
15 results on '"Forconi, Francesco"'

1. Development of a distributed international patient data registry for hairy cell leukemia

Author

Andritsos, Leslie A., primary, Anghelina, Mirela, additional, Neal, Jasmine, additional, Blachly, James S., additional, Mathur, Puneet, additional, Lele, Omkar, additional, Dearden, Claire, additional, Iyengar, Sunil, additional, Cross, Matthew, additional, Zent, Clive S., additional, Rogers, Kerry A., additional, Epperla, Narendranath, additional, Lozanski, Gerard, additional, Oakes, Christopher C., additional, Kraut, Eric, additional, Ruppert, Amy S., additional, Zhao, Qiuhong, additional, Bhat, Seema A., additional, Forconi, Francesco, additional, Banerji, Versha, additional, Handunnetti, Sasanka, additional, Tam, Constantine S., additional, Seymour, John F., additional, Else, Monica, additional, Kreitman, Robert J., additional, Saven, Alan, additional, Call, Timothy, additional, Parikh, Sameer A., additional, Ravandi, Farhad, additional, Johnston, James B., additional, Tiacci, Enrico, additional, Troussard, Xavier, additional, Tallman, Martin S., additional, Dietrich, Sascha, additional, Tadmor, Tamar, additional, Gozzetti, Alessandro, additional, Zinzani, Pier Luigi, additional, Robak, Tadeusz, additional, Quest, Graeme, additional, Demeter, Judit, additional, Rai, Kanti, additional, Fernandez, Soledad A., additional, and Grever, Michael, additional

Published
2022
Full Text
View/download PDF

2. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

Author

Maffei, Rossana, primary, Fiorcari, Stefania, additional, Martinelli, Silvia, additional, Benatti, Stefania, additional, Bulgarelli, Jenny, additional, Rizzotto, Lara, additional, Debbia, Giulia, additional, Santachiara, Rita, additional, Rigolin, Gian Matteo, additional, Forconi, Francesco, additional, Rossi, Davide, additional, Laurenti, Luca, additional, Palumbo, Giuseppe A., additional, Vallisa, Daniele, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Luppi, Mario, additional, and Marasca, Roberto, additional

Published
2017
Full Text
View/download PDF

3. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Author

Maffei, Rossana, Fiorcari, Stefania, Martinelli, Silvia, Benatti, Stefania, Bulgarelli, Jenny, Rizzotto, Lara, Debbia, Giulia, Santachiara, Rita, Rigolin, Gian Matteo, Forconi, Francesco, Rossi, Davide, Laurenti, Luca, Palumbo, Giuseppe A., Vallisa, Daniele, Cuneo, Antonio, Gaidano, Gianluca, Luppi, Mario, and Marasca, Roberto

Subjects
CHRONIC lymphocytic leukemia, CLINICAL trials, CYTOKINES, GENE expression, CANCER patients
Abstract

Lenalidomide is a therapeutically effective drug in chronic lymphocytic leukemia (CLL). Twenty-seven CLL patients were treated with lenalidomide in a phase II clinical trial. Ten patients were grouped as responders (R) and 6 as nonresponders (NR). We evaluated T lymphocytes, NK, monocytes and dendritic cells at baseline and after treatment. A gene expression analysis was performed on 16 CLL samples collected before treatment. The levels of immune cells or immune-related cytokines are not different between R and NR patients. However, CLL patients sensitive to lenalidomide clearly show a peculiar gene expression profile in leukemic cells. The most up-regulated gene (fold change =  +23 in R vs. NR) is Wnt inhibitor SHISA homolog 3 (SHISA3). SHISA3highCLL are characterized by a restrained activation of Wnt signaling and sensibility to lenalidomide-induced apoptosis. In conclusion, SHISA3 is a candidate gene for the identification of CLL patients who will benefit of lenalidomide treatment as single agent. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

4. MGA, a suppressor ofMYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

Author

De Paoli, Lorenzo, primary, Cerri, Michaela, additional, Monti, Sara, additional, Rasi, Silvia, additional, Spina, Valeria, additional, Bruscaggin, Alessio, additional, Greco, Mariangela, additional, Ciardullo, Carmela, additional, Famà, Rosella, additional, Cresta, Stefania, additional, Maffei, Rossana, additional, Ladetto, Marco, additional, Martini, Maurizio, additional, Laurenti, Luca, additional, Forconi, Francesco, additional, Marasca, Roberto, additional, Larocca, Luigi M., additional, Bertoni, Francesco, additional, Gaidano, Gianluca, additional, and Rossi, Davide, additional

Published
2012
Full Text
View/download PDF

5. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

Author

Else, Monica, primary, Dearden, Claire E., additional, Matutes, Estella, additional, Forconi, Francesco, additional, Lauria, Francesco, additional, Ahmad, Humayun, additional, Kelly, Susan, additional, Liyanage, Anandika, additional, Ratnayake, Vijitha, additional, Shankari, Jagadeesan, additional, Whalley, Ioana, additional, and Catovsky, Daniel, additional

Published
2011
Full Text
View/download PDF

9. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort

Author

Bilous, Nadiia, primary, Bomben, Riccardo, additional, Dal Bo, Michele, additional, Capello, Daniela, additional, Forconi, Francesco, additional, Laurenti, Luca, additional, Bertoni, Francesco, additional, Efremov, Dimitar G., additional, Marasca, Roberto, additional, Del Poeta, Giovanni, additional, Martina, Zoya, additional, Kryachouk, Iryna, additional, Dyagil, Iryna, additional, Gaidano, Gianluca, additional, Chumak, Anatoliy, additional, Gattei, Valter, additional, and Abramenko, Iryna, additional

Published
2010
Full Text
View/download PDF

13. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.

Author

De Paoli, Lorenzo, Cerri, Michaela, Monti, Sara, Rasi, Silvia, Spina, Valeria, Bruscaggin, Alessio, Greco, Mariangela, Ciardullo, Carmela, Famà, Rosella, Cresta, Stefania, Maffei, Rossana, Ladetto, Marco, Martini, Maurizio, Laurenti, Luca, Forconi, Francesco, Marasca, Roberto, Larocca, Luigi M., Bertoni, Francesco, Gaidano, Gianluca, and Rossi, Davide

Subjects
CHRONIC lymphocytic leukemia, LEUKEMIA
Abstract

A letter to the editor is presented in response to the research study "MGA, a suppressor of MYC, Is Recurrently Inactivated in High Risk Chronic Lymphocytic Leukemia," which appeared in the previous issue.

Published
2013
Full Text
View/download PDF

14. Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis.

Author

Forconi, Francesco, Cencini, Emanuele, Sicuranza, Anna, Sozzi, Elisa, and Lauria, Francesco

Subjects
*HAIRY cell leukemia, *CELL receptors, *IMMUNOGLOBULIN genes, *HUMAN immunogenetics, *GENETIC mutation, *B cell differentiation -- Molecular aspects
Abstract

The B cell receptor (BCR) is the functional distinguishing unit that defines any B cell. Immunoglobulin gene (IG) status is preserved in the neoplastic B cell clone and can provide an indicator of the maturation stage reached by the B cell prior to transformation. In hairy cell leukemia (HCL), several pieces of data from IG analysis provide clear hints regarding the cell of origin and the ongoing selective interactions of the tumor BCR with environmental stimuli. HCLs have variable levels of IG somatic mutations, and continue somatic mutations at low levels as well as IG class switching after transformation. More recent data also show the occurrence of selective events in the light chain of the BCR, suggesting a dominant role for IG status in the pathogenesis of HCL. Moreover, it has recently emerged that an unmutated status of the HCL IG can be associated with failure to respond to cladribine, genetic abnormalities indicative of poor outcome, and aggressive disease. These observations suggest that IG analysis may have biological and prognostic relevance in HCL and merits further characterization. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results